Central Georgia Cancer Care, PC - Macon

Central Georgia Cancer Care specializes in the diagnosis and treatment of blood disorders and various forms of cancer. The practice consists of six physicians across two locations (Macon and Warner Robins). Their goal is to provide premier oncology care and ensure the greatest level of patient satisfaction. The physicians are trained in state-of-the-art cancer-fighting technologies and participate in dozens of National Cancer Institute-sponsored clinical trials. Central Georgia Cancer Care is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)
Cancer Type: Leukemia

A Phase 3, Open Label, Randomized, Parallel, 2-Arm , Multicenter Study of Talazoparib (BMN 673) versus Physician's Choice in Germline BRCA Mutation Subjects with Locally Advanced and or Metastatic Breast Cancer, Who Have Received Prior Chemotherapy Regimens for Metastatic Disease.
Cancer Type: Breast Cancer

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

A Randomized, Double Blinded Phase III Study of Pembrolizumab (MK-3475) plus Chemotherapy vs. Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (KEYNOTE-355)
Cancer Type: Breast Cancer

An open label phase 2 study of denintuzumab mafodotin (SGN-19A-004 in combination with RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) or RCHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) compared with RCHOP alone as frontline therapy in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) Grade 3b
Cancer Type: Non-Hodgkin Lymphoma